GO Main Menu Go Main Contents Go Bottom Menu
  • Truxima® is the world's first oncology mAB biosimilar developed by Celltrion and approved by FDA and EMA.

    Truxima® image
    • Product Name : Truxima®
    • INN : Rituximab
    • Indications : Non-Hodgkin's Lymphoma(NHL), Chronic Lymphocytic Leukemia(CLL), Rheumatoid Arthritis(RA), Granulomatosis with Polyangiitis(GPA), Microscopic Polyangiitis(MPA)
    • Protein Type : Monoclonal antibody (mAb)
    • Mechanism of Action : It targets the CD20 antigen expressed on the surface of malignant B-cells and enabling the immune response that involves B-cell lysis.
    • Drug Approval Status : Korea, USA, Europe, Canada, Brazil, etc.

    This product description is for medical and educational purposes only.
    They are not intended to promote PR or sales campaigns.
    For more details, please consult a doctor or a medical specialist. This site is intended for all over the world.